Skip to main content
. 2017 Jun 27;7:4292. doi: 10.1038/s41598-017-04612-w

Figure 5.

Figure 5

ACF inhibits HSR-GBM1-Luc xenograft growth in vivo. (A) HSR-GBM1 xenografts were grown to approximately 220 mm3. Treatment was administered by intraperitoneal injections of vehicle (DMSO in saline) or ACF (8 mg/kg) for 15 injections (indicated by arrows in (A)). Tumor volume (mean +/− SEM; n = 5) is shown. (B) To determine if ACF is reaching its target in vivo, two mice (one female and one male) were euthanized on day 41 (Third daily injection and 2 hours after the last dose) and their tumors were harvested and analyzed by flow cytometry, with HSR-GBM1-Luc serving as a reference. (C,D) Microvessel density analysis for xenografts shown in (A) using IHC staining for CD31; **P < 0.01 ACF vs. vehicle (two-way ANOVA with Sidak’s multiple comparisons test).